2023-04
喜讯 | 博生吉医药TAA06注射液顺利完成I期临床试验的首例患者回输
中国苏州,2023年4月17日——博生吉医药科技,一家以突破性细胞新药研发为主要业务的国家高新技术企业,今日公告,公司自主研...
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
PersonGen BioTherapeutics (Suzhou) Co. Ltd is a biotech company focusing on developing leading-edge cellular therapeutics. The company is committed to developing CAR-related therapeutic and analytical antibodies, novel CAR- products, and allogeneic cellular therapies. The company has developed a comprehensive pipeline of products and a world-leading allogeneic off-the-shelf UCAR-Vδ1 T-cell R&D platform.
PersonGen.Anke Cellular Therapeutics Co., Ltd.
PersonGen-Anke Cellular Therapeutics Co., Ltd. is a subsidiary company and the manufacturing base of PersonGen BioTherapeutics. The company is equipped with the global-leading fully-automated, closed manufacturing system for cellular therapeutics. It also has the most advanced facilities for the manufacturing of clinical-grade DNA plasmids and lentiviruses. The company has developed fully validated manufacturing processes of CAR-T, allogeneic γδT and UCAR-γδT products.
Read More
PersonGen BioTherapeutics is one of the first company in China focusing on the development of CAR-T and other cellular immunotherapies.
We are driven by our values “Care for People, Cure Every Patient”, and is committed to being the world leader on developing allogeneic cellular therapies against tumors and autoimmunity diseases.
中国苏州,2023年4月17日——博生吉医药科技,一家以突破性细胞新药研发为主要业务的国家高新技术企业,今日公告,公司自主研...
11月28日,第16届泰州医药博览会如约于中国医药城会展交易中心盛大启幕,在每年岁末,为全球医药人搭建起思想碰撞、成果展示与合作共赢的高端平...
中国,苏州,2025年11月11日 – 博生吉医药科技(苏州)有限公司(以下简称“博生吉”)今日宣布,与长期战略合作伙伴——安徽安科生物工程...
近日,博生吉医药宣布,其自主研发的体内细胞治疗产品LV009注射液已完成首例患者给药,标志着博生吉的CAR-T/NK技术正式从“体外定制”迈...
近日,第十届“科创江苏”创新创业大赛生命科学领域决赛在南京圆满收官,博生吉医药科技(苏州)有限公司凭借在细胞治疗领域的突破性技术成果与产业化...
Conceptual Pilot Study, Patient Recruitment
Read More